Company Overview
About Numerion Labs
Numerion Labs, formerly known as Atomwise, is an AI-driven drug discovery company that uses deep learning to accelerate the identification of small molecule drug candidates. The company''s core technology, AtomNet, is a convolutional neural network trained on vast datasets of protein-ligand interactions to predict binding affinity and drug-likeness at scale. In October 2025, Atomwise rebranded as Numerion Labs, reflecting a sharpened strategic focus on ultra-fast virtual screening and the development of its APEX platform for hyper-scalable chemical library screening — a capability validated in partnership with NVIDIA.
Business Model & Competitive Advantage
AtomNet''s track record is well-documented: in a prospective study spanning 22 internal pharma programs and 296 academic projects (318 targets total), AtomNet-guided campaigns achieved hit identification in 73–75% of targets with average hit rates of 5–7.6% — positioning the platform as a viable replacement for traditional high-throughput screening (HTS) in the first step of small-molecule discovery. Numerion Labs has collaborated with over 250 partners including pharmaceutical and biotech companies, academic institutions, and global health organizations through the AIMS (Atomwise Initiatives for Medical Startups and Pharma) program.
Competitive Landscape 2025–2026
The company''s most significant commercial partnership is with Sanofi, a multi-target AI drug discovery collaboration that includes approximately $20M in upfront and near-term payments and up to approximately $1.2 billion in potential milestones and royalties. Numerion Labs is headquartered in San Francisco and is a Y Combinator alumnus. As the AI drug discovery field matures — with 170+ AI-discovered programs now in clinical development globally — Numerion Labs is positioned as a foundational platform provider with deep validation data and established pharma partnerships.
Key Differentiators
Strong Challenger
Numerion Labs is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Genesis Therapeutics
Genesis Therapeutics — now operating as Genesis Molecular AI — is a clinical-stage biotechnology company founded in 2019 and headquartered in Burlingame, California. The company applies artificial int
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare Numerion Labs with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Numerion Labs? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Numerion Labs Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Numerion Labs vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →